Hackberry Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 10-12-2024
- Paid Up Capital ₹ 1.00 M
as on 10-12-2024
- Company Age 8 Year, 2 Months
- Last Filing with ROC 31 Mar 2020
- Revenue -25.88%
(FY 2020)
- Profit -100.33%
(FY 2020)
- Ebitda -97.91%
(FY 2020)
- Net Worth -0.30%
(FY 2020)
- Total Assets -47.29%
(FY 2020)
About Hackberry Pharmaceutical
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Izharul Haque, Shabbirul Haque, Shimpi Kumari, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999BR2016PTC032676
- Company No.
032676
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Oct 2016
- Date of AGM
29 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Araria, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hackberry Pharmaceutical?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Izharul Haque  | Director | 05-Oct-2016 | Current |
| Shabbirul Haque | Director | 05-Oct-2016 | Current |
| Shimpi Kumari | Director | 05-Oct-2016 | Current |
| Nisha | Director | 05-Oct-2016 | Current |
Financial Performance of Hackberry Pharmaceutical.
Hackberry Pharmaceutical Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 25.88% decrease. The company also saw a substantial fall in profitability, with a 100.33% decrease in profit. The company's net worth dipped by a decrease of 0.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hackberry Pharmaceutical?
In 2018, Hackberry Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Raushan Electronics Private LimitedActive 1 year 11 months
Izharul Haque and Shabbirul Haque are mutual person
- Raushan Delight Private LimitedActive 3 months 10 days
Izharul Haque and Shabbirul Haque are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hackberry Pharmaceutical?
Unlock and access historical data on people associated with Hackberry Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hackberry Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hackberry Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
